QuidelOrtho Quarterly Cash Flow Statement
NASDAQ: QDELHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
QuidelOrtho free cash flow
In the quarter ended Jun 28, 2026, QuidelOrtho generated -$110.6 million of operating cash flow and spent $25.5 million on capital expenditures. That left free cash flow of -$136.1 million, a free-cash-flow margin of -21.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
QuidelOrtho cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-28 | Q1 20262026-03-29 | Q4 20252025-12-28 | Q3 20252025-09-28 | Q2 20252025-06-29 | Q1 20252025-03-30 | Q4 20242024-12-29 | Q3 20242024-09-29 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-10-01 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -92.90M | -91.80M | -130.70M | -733.00M | -255.40M | -12.70M | -178.40M | -19.90M | -147.70M | -1.71B | 7.00M | -12.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | -2648.57% | — | — | -3595.90% | -76.90% | -166.15% |
| Depreciation & Amortization | 116.70M | 112.90M | 112.50M | 112.10M | 110.30M | 107.10M | 109.30M | 113.10M | 116.10M | 114.90M | 115.40M | 113.10M |
| Stock-Based Compensation | 12.00M | 10.70M | 10.80M | 10.70M | 12.80M | 11.60M | 9.60M | 12.30M | 11.20M | 9.00M | 12.30M | 14.10M |
| Change in Working Capital | -71.00M | -115.30M | 121.30M | -120.90M | -65.10M | -69.10M | -44.10M | 18.10M | -65.20M | -83.50M | -22.20M | -92.40M |
| Operating Cash Flow | -110.60M | -33.00M | 131.90M | -45.50M | -46.80M | 65.60M | 63.70M | 117.90M | -97.90M | -700.00K | 80.40M | 41.50M |
| Capital Expenditures | -25.50M | -34.00M | -45.30M | -49.20M | -37.50M | -56.20M | -47.20M | -46.50M | -35.30M | -66.10M | -48.60M | -43.40M |
| Investing Cash Flow | -107.30M | -34.00M | -49.60M | -53.90M | -33.00M | -56.20M | -37.90M | -56.50M | -35.30M | -20.20M | -55.10M | -21.30M |
| Share Repurchases | — | — | — | — | — | — | — | — | — | — | -7.20M | — |
| Debt Issued | 100.00M | 12.60M | 13.10M | 2.55B | 0 | 0 | 0 | — | — | — | 0 | 0 |
| Debt Repaid | -19.60M | -22.40M | -1.60M | -2.22B | -36.00M | -36.00M | -36.00M | -3.30M | -51.80M | -51.90M | -52.30M | -51.90M |
| Financing Cash Flow | 200.60M | 37.60M | -11.10M | 46.00M | 103.30M | 17.60M | -68.90M | -26.30M | 162.50M | -18.50M | -57.80M | -48.70M |
| Net Change in Cash | -17.00M | -29.40M | 71.70M | -53.60M | 24.50M | 28.70M | -45.50M | 36.50M | 28.50M | -40.50M | -30.40M | -29.70M |
| Free Cash Flow | -136.10M | -67.00M | 86.60M | -94.70M | -84.30M | 9.40M | 16.50M | 71.40M | -133.20M | -66.80M | 31.80M | -1.90M |
This table shows 12 quarterly periods of QuidelOrtho's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow QDEL's reporting calendar. What is a cash flow statement?